March 6, 2018 09:51 AM EST
Financing

View­Point Ther­a­peu­tics gets $35M to ad­vance non-sur­gi­cal al­ter­na­tive for cataracts, pres­by­opia

Amber Tong

With help from a so­cial­ly con­scious fund, San Fran­cis­co pro­tein mis­fold­ing up­start View­Point Ther­a­peu­tics has raised $35 mil­lion to take its eye drugs through proof …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times